将患者的整体变化印象（PGIC）评分与每月偏头痛天数进行比较，以评估抗降钙素基因相关肽（CGRP）单克隆抗体的治疗持久性。
Patients' Global Impression of Change (PGIC) Score Compared to Monthly Migraine Days to Evaluate Treatment Persistence With Anti-CGRP Monoclonal Antibodies.
作者信息
Romozzi Marina, Vollono Catello, Calabresi Paolo, De Cesaris Francesco, Iannone Luigi Francesco
机构信息
Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy.
Neurologia, Dipartimento di Neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
出版信息
Ann Clin Transl Neurol. 2025 Jun;12(6):1292-1295. doi: 10.1002/acn3.70053. Epub 2025 Apr 17.
This study assessed whether continued treatment with anti-CGRP monoclonal antibodies (mAbs) is driven more by reductions in monthly migraine days (MMDs) or patients' global impression of change (PGIC), a patient-reported outcome. Among 169 patients treated with anti-CGRP mAbs, 21.3% discontinued due to ineffectiveness. PGIC responders (≥ 5) at month 12 were 69.8%, whereas MMD responders (≥ 50% reduction) were 59.2%. Both were significantly associated with discontinuation (PGIC: χ = 33.474, φ = 0.445; MMD: χ = 29.884, φ = 0.421; p < 0.0001). PGIC showed a stronger correlation with discontinuation (r = 0.541) than MMD reduction (r = 0.470). These findings highlight PGIC as strongly associated with treatment response, supporting the need for PROMs in evaluating migraine treatment effectiveness.
本研究评估了抗降钙素基因相关肽单克隆抗体（mAbs）的持续治疗是更多地由每月偏头痛天数（MMD）的减少还是由患者报告的结局——患者整体变化印象（PGIC）所驱动。在169例接受抗降钙素基因相关肽单克隆抗体治疗的患者中，21.3%因无效而停药。12个月时PGIC应答者（≥5）为69.8%，而MMD应答者（减少≥50%）为59.2%。两者均与停药显著相关（PGIC：χ=33.474，φ=0.445；MMD：χ=29.884，φ=0.421；p<0.0001）。与MMD减少（r=0.470）相比，PGIC与停药的相关性更强（r=0.541）。这些发现突出了PGIC与治疗反应密切相关，支持在评估偏头痛治疗效果时使用患者报告结局指标的必要性。
Zotero 插件